Indeed, recent data indicates very high costs related to the use of SGLT2 inhibitors and GLP-1 receptor agonists among individuals with diabetes in particular [22], as well as for PCSK9 inhibitor therapy in the overall ASCVD population [23]. This evidence concerns the gene GLP1R and diabetes mellitus.